Publications by authors named "S M M Hosseini-Moghaddam"
Background: A considerable knowledge gap exists in predicting severe Pneumocystis pneumonia (PCP) outcomes following PCP diagnosis.
Methods: In this retrospective cohort, we studied immunocompromised patients with PCP admitted to 5 University Health Network centers in Canada (2011-2022). The study outcome included severe PCP, a composite of 21-day ICU admission or 28-day all-cause mortality.
Background: There are few interventional studies using CMV cell-mediated immunity (CMI) to guide antiviral prophylaxis. We assessed the Quantiferon-CMV (QTF-CMV) assay to guide CMV prophylaxis duration in high-risk organ transplant recipients.
Methods: A single-arm, multicenter, prospective interventional study including high-risk kidney, pancreas, liver, and heart transplant recipients who were either donor CMV-seropositive, recipient-seronegative (D + /R - ) or recipient-seropositive with antithymocyte globulin (R + /ATG) induction.
Article Synopsis
- HIV-negative immunocompromised patients, particularly solid organ transplant (SOT) recipients, exhibit more severe presentations and worse outcomes from Pneumocystis pneumonia (PCP) compared to non-SOT patients.
- A retrospective study at the University Health Network analyzed 118 patients diagnosed with PCP and found significant differences in symptoms, mortality rates, ICU admissions, and mechanical ventilation needs between SOT and non-SOT groups.
- The study concluded that SOT patients are at a higher risk for severe outcomes from PCP, prompting a call for further research into the underlying biological factors driving these differences.
Background: People with HIV are at a greater risk of end-stage kidney disease than the general population. Considering the risk of death after end-stage kidney disease, access to renal transplantation in people with HIV is critically important.
Methods: We included all adult patients on chronic dialysis in Ontario, Canada, between 1 April 2007 and 31 December 2020.
Article Synopsis
- A multicenter study examined the effects of adjunctive glucocorticoid therapy (AGT) on all-cause ICU admission and death rates among solid organ transplant recipients (SOTRs) with Pneumocystis jirovecii pneumonia (PJP) across several countries.
- The study included 172 SOTRs with an average age of 60, and found ICU admission rates at 43.4% and death rates at 20.8%.
- Results showed that AGT did not significantly lower the risk of ICU admission, death, or improve respiratory function, indicating a need to reconsider its routine use in PJP treatment for SOTRs and call for further research.